Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.35 |
| ▸ | POLG | P54098 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | POLD1 | P28340 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21418540 | 0.91 | P2RY2 (0.39) | P2RY2P2RY4POLGPOLBPOLA1 | |
| SCHEMBL21418538 | 0.91 | P2RY2 (0.36) | P2RY2P2RY4POLGPOLBPOLA1 | |
| SCHEMBL16575905 | 0.83 | P2RY2 (0.43) | P2RY2P2RY4POLGPOLBPOLA1 | |
| SCHEMBL17976659 | 0.83 | P2RY2 (0.43) | P2RY2P2RY4POLGPOLBPOLA1 | |
| SCHEMBL17971852 | 0.83 | P2RY2 (0.43) | P2RY2P2RY4POLGPOLBPOLA1 | |
| SCHEMBL21418546 | 0.83 | P2RY2 (0.44) | P2RY2P2RY4POLA1P2RY14P2RY6 | |
| SCHEMBL21418545 | 0.82 | P2RY2 (0.54) | P2RY2P2RY4POLA1P2RY14P2RY6 | |
| SCHEMBL21418659 | 0.82 | POLG (0.47) | P2RY2P2RY4POLGP2RY6 | |
| SCHEMBL21418537 | 0.78 | P2RY2 (0.52) | P2RY2P2RY4P2RY14P2RY6 | |
| SCHEMBL21418393 | 0.78 | POLG (0.34) | P2RY2P2RY4POLGPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | P2RY2 316/4885P2RY4 230/4885POLG 601/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | P2RY2 452/4885P2RY4 288/4885POLG 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.